ENGN · enGene Therapeutics Inc
United States · RS rating 17 · As of 2026-11-03
| Price | 1.62 USD |
|---|---|
| 1-day change | +11.7% |
| RS rating (overall / 1M / 3M / 12M) | 17 / 30 / 46 / 10 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 16 / 4 / 27 |
| Industry group (rank) | Medical-Generic Drugs (136) |
| EPS growth Q/Q | +2.3% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +86.7% |
| Market cap (USD) | $545.3M |